Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nabriva Therape Ads (NBRV)

Nabriva Therape Ads (NBRV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 750,360
  • Shares Outstanding, K 946,230
  • Annual Sales, $ 9,480 K
  • Annual Income, $ -82,760 K
  • 60-Month Beta 2.43
  • Price/Sales 74.79
  • Price/Cash Flow N/A
  • Price/Book 35.61
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.08
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/11/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.18
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5250 +50.23%
on 05/13/20
1.2000 -34.28%
on 05/29/20
+0.2307 (+41.34%)
since 05/05/20
3-Month
0.4850 +62.62%
on 04/21/20
1.5441 -48.92%
on 03/06/20
-0.7513 (-48.79%)
since 03/05/20
52-Week
0.4850 +62.62%
on 04/21/20
2.7700 -71.53%
on 08/20/19
-1.5613 (-66.44%)
since 06/05/19

Most Recent Stories

More News
Implied Volatility Surging for Nabriva (NBRV) Stock Options

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

NBRV : 0.7887 (-0.54%)
Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 0.7887 (-0.54%)
Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA(TM) (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

-- If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe

NBRV : 0.7887 (-0.54%)
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the publication...

NBRV : 0.7887 (-0.54%)
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates

-Cash runway extended into the fourth quarter of 2020 through judicious resource management-

NBRV : 0.7887 (-0.54%)
Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 0.7887 (-0.54%)
Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 0.7887 (-0.54%)
Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)

Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NBRV : 0.7887 (-0.54%)
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates....

ACAD : 45.61 (-0.31%)
NBRV : 0.7887 (-0.54%)
KALA : 13.59 (+1.72%)
LCTX : 0.8900 (-2.20%)
XENLETA(R) (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that...

NBRV : 0.7887 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NBRV with:

Business Summary

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins,...

See More

Key Turning Points

2nd Resistance Point 0.8629
1st Resistance Point 0.8258
Last Price 0.7887
1st Support Level 0.7508
2nd Support Level 0.7129

See More

52-Week High 2.7700
Fibonacci 61.8% 1.8971
Fibonacci 50% 1.6275
Fibonacci 38.2% 1.3579
Last Price 0.7887
52-Week Low 0.4850

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar